AstraZeneca Young Health Programme to partner with UNICEF to prevent non-communicable diseases among young people

The partnership will galvanise a global advocacy movement to reach
more than five million young people over the next six years
 

AstraZeneca announced today that it will support UNICEF with a $12.5 million grant to support programming which will reach more than five million young people, train 1,000 youth advocates, and positively shape public policy around the world, over the next six years.

The announcement follows AstraZeneca’s decision in October 2019 to continue to fund its Young Health Programme to 2025 with an overall commitment of $35m (£28m).

The AstraZeneca Young Health Programme will work with UNICEF and other partners to raise awareness of the risks and effects of non-communicable diseases (NCDs) such as cardiovascular disease, preventable cancers and mental health conditions among young people and key decision-makers.

The World Health Organisation (WHO) identifies NCDs as the number one cause of death worldwide1 and found that 70% of premature deaths from NCDs can be linked back to behaviours that first appear in adolescence2. Similarly, the World Economic Forum (WEF) has predicted that NCDs will cost the worldwide economy more than $47 trillion in lost productivity and wages by 20303.



Pascal Soriot, Chief Executive Officer, said: “We believe in the power of young people to change the trajectory of the staggering burden of disease we face today, all over the world. Improving the health outcomes of future generations is a critical part of developing strong and stable healthcare systems, which in turn support sustainable markets and the economic prosperity of nations.”

Since its launch in 2010, the Young Health Programme has reached more than 3.5 million young people across six continents and trained more than 50,000 peer educators.

Gary Stahl, Director, UNICEF Private Fundraising and Partnerships, said: “The health and futures of young people must not be compromised by unhealthy lifestyles and behaviours. I am happy that UNICEF is joining a coalition of committed partners with the support of AstraZeneca to bring attention to NCDs which are now the world’s biggest killers. The burden of these diseases is closely linked to socio-economic factors and more work needs to be done on delivering the right messages through the right channels in countries to encourage healthy behaviours.”

The other allies in the Young Health Programme are founding partner, and community-based programming lead, Plan International, youth engagement and development lead One Young World, and more than 30 other non-profit partners around the world, all working to improve health outcomes for young people through thoughtful programming, research and youth engagement activities.

The Young Health Programme

Since 2010 the Young Health Programme has reached over three million young people, through a mix of programmes, advocacy and research activities designed to increase awareness and understanding of NCD prevention. These have ranged over 24 countries and six continents from Australia to Zambia. Programmes range from one-to-one mentoring in Sweden, to long-running community-based behaviour change programmes involving hundreds of thousands of young people in Brazil and India. The methods may vary, but the drive is always the same – to help young people to lead longer, happier and healthier lives. For more information please visit younghealthprogrammeyhp.com.



UNICEF

UNICEF is the world’s leading organisation for children, promoting the rights and wellbeing of every child, in everything we do. Together with our partners, UNICEF works in 190 countries and territories to translate that commitment into practical action, focusing special effort on reaching the most vulnerable and excluded children, to the benefit of all children, everywhere.

Unicef UK raises funds to protect children in danger, transform their lives and build a safer world for tomorrow’s children. As a registered charity we raise funds through donations from individuals, organisations and companies and we lobby and campaign to keep children safe. Unicef UK also runs programmes in schools, hospitals and with local authorities in the UK.

For more information please visit unicef.org.uk.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

Contacts

Media Relations

 

 

Gonzalo Viña

 

+44 203 749 5916

Rob Skelding

Oncology

+44 203 749 5821

Rebecca Einhorn

Oncology

+1 301 518 4122

Matt Kent

BioPharmaceuticals

+44 203 749 5906

Angela Fiorin

BioPharmaceuticals

+44 1223 344 690

Jennifer Hursit

Other

+44 203 749 5762

Christina Malmberg Hägerstrand

Sweden

+46 8 552 53 106

Michele Meixell

US

+1 302 885 2677

     

Investor Relations

 

 

Thomas Kudsk Larsen

 

+44 203 749 5712

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

BioPharmaceuticals
(Cardiovascular, Metabolism)

+44 203 749 5711

Nick Stone

BioPharmaceuticals
(Renal) Environmental, Social and Governance

+44 203 749 5716

Josie Afolabi

BioPharmaceuticals (Respiratory)

Other medicines

+44 203 749 5631

Craig Marks

Finance

Fixed income

+44 7881 615 764

Jennifer Kretzmann

Corporate access

Retail investors

+44 203 749 5824

US toll-free

 

+1 866 381 72 77

 

References

1. https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases

2. WHO. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: World Health Organization, 2009.

3. http://www3.weforum.org/docs/WEF_Harvard_HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf

 

tags

  • Sustainability
  • Corporate and financial
  • Partnering